• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role

    11/8/23 9:50:00 AM ET
    $BMY
    $ILMN
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $BMY alert in real time by email

    New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal of precision medicine.

    According to Straits Research, "North America is dominating the market with the highest revenue and is expected to reach USD 97.32 billion in 2030, growing at a CAGR of 9.7% during the forecast period,"

    Download Free Sample Report PDF @ https://straitsresearch.com/report/precision-medicine-market/request-sample

    Key Drivers

    DNA sequencing technology has undergone significant technological advancements, which have paved the way for a deeper understanding of some diseases like cancer. Depending on the genetic profiles of those individuals, the advancements have made it possible to develop treatments that are better suited to them. Patients with breast, lung, or colorectal cancer who have undergone genetic testing as part of routine patient care can measure this molecular transformation of medicine. As a result, the process's accuracy and the time required to finish it have increased. With the collection of more medical data, there has been an increase in understanding of how the treatment a patient receives affects the patient's overall health. It is possible to use precision medicine for preventive care when interventions target disease risk factors to lower the disease risk. One example of this would be the treatment of high blood pressure to prevent patients from experiencing heart attacks or strokes.

    Growth Opportunities

    Most precision medicine providers focus on developed markets, leaving emerging markets untapped. Large populations at risk for diseases requiring gene sequencing in China, India, Australia, the Middle East, and Africa present an opportunity to expand the precision medicine market. Genetics and precision medicine have made significant progress in developing countries over the past decade regarding regulations, product approvals, and implementation of novel methods and procedures in healthcare.

    Searching for mendelian germline genetic mutations, such as those in cancer genetics, is likely the first step for emerging nations' public healthcare systems. Private healthcare investment funds help small innovative players develop new genetic tests in emerging regions. Developing nations' proper and uncomplicated approval of GINA helped ban genetic discrimination in health insurance and employment. This creates a modern and humanized genomic medicine environment in the country.

    Regional Analysis

    The North American segment dominates the market with the highest revenue, and The United States dominates North America's precision medicine market. Advanced research and development in molecular diagnostics and targeted therapeutics have significantly aided our understanding of the biology of various infectious diseases and forms of cancer, such as lung cancer, breast cancer, and colorectal cancer.

    Several well-established diagnostics manufacturers in North America are focusing on expanding their portfolios of NGS-based molecular diagnostics and collaborating with service providers and pharmaceutical behemoths to co-market molecular diagnostics solutions alongside their complementary precision medicine solutions. In addition, the U.S. government finances new molecular diagnostics and precision medicine start-ups.

    Key Highlights

    • The global precision medicine market size is projected to reach USD 280.67 billion by 2030, growing at a CAGR of 11.12% during the forecast period (2022–2030).
    • Based on the ecosystem, the global precision medicine market is segmented into sciences, precision diagnostics, precision therapeutics, and digital health and information technology. The precision therapeutics segment is dominating the market and is expected to grow at a CAGR of 11.62% during the forecast period.
    • Based on application, the global precision medicine market is segmented into oncology, neurology/psychiatry, infectious diseases, gastroenterology, cardiovascular, endocrinology, rheumatology, etc. The oncology segment is the most dominant and is expected to grow at a CAGR of 11.21% during the forecast period.

    Competitive Analysis

    The global precision medicine market's major key players are Bristol-Myers Squibb Company, Illumina, Inc., Pacific Biosciences of California, Inc., AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Premaitha Health plc, QIAGEN N.V., Johnson and Johnson, and Asuragen, Inc.

    Market News

    • May 2022- Illumina Introduced New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy. The first companion diagnostic claim for Illumina's TruSightTM Oncology Comprehensive (EU) test enables targeted therapy for patients with NTRK fusion cancer using Bayer's VITRAKVI® (larotrectinib).
    • May 2022- Illumina and Allegheny Health Network Assessed In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care. Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving Western Pennsylvania, have partnered to evaluate the impact of in-house comprehensive genomic profiling (CGP) on patient care.
    • June 2022- Bristol Myers Squibb Acquired Turning Point Therapeutics, a Leading Precision Oncology Company. Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) have announced a definitive merger agreement.

    Global Precision Medicine Market: Segmentation

    By Ecosystem

    • Applied Sciences
    • Precision Diagnostics
    • Precision Therapeutics
    • Digital Health and Information Technology

    By Application

    • Oncology
    • Neurology/psychiatry
    • Infectious diseases
    • Gastroenterology
    • Cardiovascular
    • Endocrinology
    • Rheumatology

    By Regions

    • North America
    • Europe
    • Asia-Pacific
    • Rest-of-the-World (ROW)

    Get Detailed Market Segmentation @ https://straitsresearch.com/report/precision-medicine-market/segmentation

    About Straits Research Pvt Ltd.

    Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, specially designed and presented for decision making and ROI.

    Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

    For more information on your target market, please contact us below:

    Phone: +1 646 480 7505 (the U.S.)

    +91 8087085354 (APAC)

    +44 208 068 9665 (the U.K.)

    Email: [email protected]

    Follow Us: LinkedIn | Facebook | Instagram | Twitter



    Primary Logo

    Get the next $BMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMY
    $ILMN
    $TPTX

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    11/13/2025$45.00Sector Perform
    Scotiabank
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    More analyst ratings

    $BMY
    $ILMN
    $TPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Bristol-Myers with a new price target

    Scotiabank initiated coverage of Bristol-Myers with a rating of Sector Perform and set a new price target of $45.00

    11/13/25 9:12:36 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Bristol-Myers downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Bristol-Myers from Outperform to Neutral and set a new price target of $42.00

    8/5/25 7:09:09 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $ILMN
    $TPTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $ILMN
    $TPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Strategy/Corp Development Wedel Christensen Jakob covered exercise/tax liability with 307 shares and sold $70,969 worth of shares (549 units at $129.27), decreasing direct ownership by 7% to 10,952 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    12/9/25 4:15:35 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M returned $39,661 worth of shares to the company (323 units at $122.79), decreasing direct ownership by 2% to 18,210 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/13/25 4:49:15 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M covered exercise/tax liability with 398 shares, decreasing direct ownership by 2% to 18,533 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/7/25 4:33:18 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $BMY
    $ILMN
    $TPTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb Announces Dividend Increase

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026. This quarterly dividend represents a 1.6% increase over last year's quarterly rate of sixty-two cents ($0.62) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2026 is $2.52 per share. This marks the 17th consecutive year that the company has increased its dividend and the 94

    12/10/25 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

    Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer ("TNBC") show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levelsData highlight the potential of pumitamig for patients with TNBC, including PD-L1 low or negative (CPS<10) TNBC which has limited treatment options and high unmet needData are consistent with the previously reported data from the 1L TNBC Phase 1b/2 trial con

    12/9/25 7:00:00 AM ET
    $BMY
    $BNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

    Bristol Myers Squibb (NYSE:BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include updates from the company's targeted protein degradation pipeline, including data on first-in-class investigational lymphoma CELMoD™ agent golcadomide and first-in-class BCL6 ligand-directed degrader BMS-986458; alongside long-term results for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, from the Phase 3 TRANSFORM and Phase 2 TRANSCEND FL trials. "The data presented at ASH represent a significant step

    12/8/25 4:30:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $ILMN
    $TPTX
    SEC Filings

    View All

    SEC Form 8-K filed by Illumina Inc.

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    11/25/25 5:06:36 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Bristol-Myers Squibb Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    11/18/25 4:41:56 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Illumina Inc.

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    11/12/25 4:59:57 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $BMY
    $ILMN
    $TPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:18:28 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $BMY
    $ILMN
    $TPTX
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Announces Dividend Increase

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026. This quarterly dividend represents a 1.6% increase over last year's quarterly rate of sixty-two cents ($0.62) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2026 is $2.52 per share. This marks the 17th consecutive year that the company has increased its dividend and the 94

    12/10/25 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

    Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basisGAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per shareFor fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (1.5%) to (0.5%), up from (2.5%) to (1.5%)Revenue growth outside of China in the range of 0.5% - 1.5% on a constant currency basis, with no ch

    10/30/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported third quarter 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed third quarter 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives

    10/30/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $ILMN
    $TPTX
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $BMY
    $ILMN
    $TPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care